What is Lisata Therapeutics, Inc.'s earnings per share (EPS)?

Lisata Therapeutics, Inc. (LSTA) reported diluted earnings per share of -$1.91 for fiscal year 2025. This represents a 20.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lisata Therapeutics, Inc. (LSTA) Financials

LSTA

FY2025 annual

Revenue $170K -83.0% YoY

Net Income -$16.6M +17.0% YoY

EPS (Diluted) -$1.91 +20.4% YoY

Free Cash Flow -$16.0M +17.5% YoY

Market Cap $13.6M as of Oct 5, 2026

Price / Sales 80.1x on $170K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.7x on $8.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LSTA SEC filings page.

Lisata Therapeutics, Inc. (LSTA) reported $170K in revenue for fiscal year 2025, down 83.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LSTA FY2025 2026-10-03

The business remains development-stage: tiny, shrinking revenue sits beside persistent R&D spending and annual cash consumption.

Earnings and cash flow move together: FY2025 net loss was $16.6M while operating cash outflow was $15.9M, indicating little distortion from working-capital movements or non-cash accounting items. Yet revenue fell 83.0% from FY2024 while R&D remained $7.9M, so the cost base is still principally funding development rather than supporting a revenue engine.

Scale has not yet absorbed fixed costs. Revenue declined from $1.0M in FY2024 to $170K in FY2025, while the operating margin widened from -22.4% to -107.1%; the worsening percentage is driven mainly by the very small revenue denominator, not a conventional mature-business margin cycle.

The balance sheet is shrinking alongside the losses: total assets fell 49.3% to $17.7M, while liabilities were $3.1M and debt-to-equity was only 0.2x in FY2025. The liquidity measure equaled 12 months of the latest reported operating outflow, but annual free-cash-flow outflow still reached $16.0M, showing that reported liquidity is being consumed by ongoing operations.

Financial Health Signals

Financial health score not available

Lisata Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-44.34

Lisata Therapeutics, Inc. scores -44.34, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($13.6M) relative to total liabilities ($3.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Lisata Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Lisata Therapeutics, Inc. reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

Lisata Therapeutics, Inc. generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

EBITDA

-$4.0M

YoY+17.3%

QoQ+19.3%

Lisata Therapeutics, Inc.'s EBITDA was -$4.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.3% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.

Net Income

-$2.9M

YoY+37.1%

QoQ+34.8%

Lisata Therapeutics, Inc. reported -$2.9M in net income in Q2 2026. This represents an increase of 37.1% from the same quarter a year earlier. Against the prior quarter it is up 34.8%.

EPS (Diluted)

-$0.32

YoY+40.7%

QoQ+36.0%

Lisata Therapeutics, Inc. earned -$0.32 per diluted share (EPS) in Q2 2026. This represents an increase of 40.7% from the same quarter a year earlier. Against the prior quarter it is up 36.0%.

Cash & Balance Sheet

Free Cash Flow

-$2.6M

YoY+33.0%

QoQ+14.1%

Lisata Therapeutics, Inc. recorded an outflow of $2.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 33.0% from the same quarter a year earlier. Against the prior quarter it is up 14.1%.

Cash & Debt

$10.4M

YoY-38.0%

QoQ-20.0%

5Y CAGR-4.2%

10Y CAGR+0.1%

Lisata Therapeutics, Inc. held $10.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+2.9%

QoQ-1.0%

5Y CAGR-31.4%

10Y CAGR+4.3%

Lisata Therapeutics, Inc. had 9M shares outstanding in Q2 2026. This represents an increase of 2.9% from the same quarter a year earlier. Against the prior quarter it is down 1.0%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-35.5%

YoY-13.4pp

QoQ+5.6pp

Lisata Therapeutics, Inc.'s ROE was -35.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 13.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.6 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$584K

YoY-74.1%

QoQ-51.5%

Lisata Therapeutics, Inc. invested $584K in research and development in Q2 2026. This represents a decrease of 74.1% from the same quarter a year earlier. Against the prior quarter it is down 51.5%.

Capital Expenditures

Lisata Therapeutics, Inc. reported no capital expenditure in Q2 2026.

Share Buybacks

Not reported for Q2 2026.

LSTA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$170K-83.0%	$1.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	$35.3M+56.9%	$22.5M+25.4%	$17.9M+22.3%	$14.7M+2.4%	$14.3M+42.6%	$10.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$31.1M+54.5%	$20.2M+28.6%	$15.7M+21.1%	$12.9M+8.4%	$11.9M+38.2%	$8.6M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4.1M+78.1%	$2.3M+3.0%	$2.3M+31.3%	$1.7M-27.7%	$2.4M+69.6%	$1.4M
R&D Expenses	N/A	$7.9M-29.9%	$11.3M-11.0%	$12.7M-2.5%	$13.1M-26.1%	$17.7M+91.1%	$9.3M-14.3%	$10.8M+42.2%	$7.6M-52.1%	$15.8M-5.1%	$16.7M-30.1%	$23.9M-18.1%	$29.2M+72.6%	$16.9M+61.9%	$10.5M+35.4%	$7.7M
SG&A Expenses	N/A	$10.4M-13.6%	$12.1M-6.9%	$13.0M-8.3%	$14.1M+23.2%	$11.5M+16.0%	$9.9M+6.4%	$9.3M-1.0%	$9.4M-20.1%	$11.8M-8.2%	$12.8M-57.3%	$30.0M-2.6%	$30.8M+42.5%	$21.6M-3.1%	$22.3M-19.4%	$27.7M
Operating Income	N/A	-$18.2M+18.7%	-$22.4M+12.8%	-$25.7M+55.4%	-$57.6M-98.3%	-$29.1M-51.7%	-$19.1M+4.7%	-$20.1M-18.3%	-$17.0M+38.4%	-$27.6M+6.5%	-$29.5M+74.1%	-$113.8M-97.2%	-$57.7M-56.9%	-$36.8M-21.1%	-$30.4M+10.6%	-$34.0M
EBITDA	N/A	-$18.1M+18.8%	-$22.2M+12.9%	-$25.5M+55.6%	-$57.5M-98.4%	-$29.0M-52.2%	-$19.0M+4.7%	-$20.0M-19.1%	-$16.8M+38.3%	-$27.2M+6.2%	-$29.0M+74.0%	-$111.7M-99.1%	-$56.1M-56.8%	-$35.8M-21.9%	-$29.4M+9.8%	-$32.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$5K-98.7%	$378K-78.8%	$1.8M-16.4%	$2.1M+181.7%	$756K+168.5%	$281K-82.2%	$1.6M-40.4%	$2.6M
Income Tax	N/A	-$962K-20.6%	-$798K+65.8%	-$2.3M+6.0%	-$2.5M-64.4%	-$1.5M+86.1%	-$10.9M	$0	$0+100.0%	-$11.5M	$0+100.0%	-$17.2M-16448.2%	-$104K-113.4%	$780K+544.4%	-$176K	$0
Net Income	N/A	-$16.6M+17.0%	-$20.0M+4.1%	-$20.8M+61.6%	-$54.2M-97.4%	-$27.5M-237.0%	-$8.2M+57.9%	-$19.4M-19.8%	-$16.2M-170.4%	$23.0M+170.4%	-$32.7M+59.7%	-$81.0M-47.6%	-$54.9M-40.8%	-$39.0M+27.5%	-$53.8M-14.1%	-$47.1M
EPS (Basic)	N/A	-$1.91+20.4%	-$2.40+7.0%	-$2.58+75.4%	-$10.47-40.5%	-$7.45-1305.7%	-$0.53	N/A	-$1.67-165.2%	$2.56+151.3%	-$4.99	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.64	-$1.91+20.4%	-$2.40+7.0%	-$2.58	-$10.47	-$7.45	-$0.53	N/A	N/A	$2.56+151.3%	-$4.99	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	9M+4.3%	8M+3.2%	8M	5M	4M	15M	N/A	10M+8.0%	9M+37.0%	7M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0-100.0%	$0	N/A	$0	$70K	$0	N/A	$0
R&D Expenses	$584K-74.1%	$1.2M-53.7%	N/A	$2.0M-22.9%	$2.3M-13.4%	$2.6M-19.7%	N/A	$2.5M-24.8%
SG&A Expenses	$3.4M+26.9%	$3.7M+15.2%	N/A	$2.5M-12.1%	$2.7M-8.1%	$3.2M-3.4%	N/A	$2.8M+8.1%
Operating Income	-$4.0M+18.0%	-$4.9M+15.5%	N/A	-$4.4M+17.3%	-$4.9M+11.9%	-$5.8M+11.4%	N/A	-$5.3M+10.5%
EBITDA	-$4.0M+17.3%	-$4.9M+14.9%	N/A	-$4.4M+17.5%	-$4.8M+11.9%	-$5.8M+11.5%	N/A	-$5.3M+10.5%
Income Tax	$0	-$387K+59.8%	N/A	$0	$0	-$962K-20.6%	N/A	$0
Net Income	-$2.9M+37.1%	-$4.5M+5.0%	N/A	-$4.2M+13.8%	-$4.7M+7.6%	-$4.7M+12.5%	N/A	-$4.9M+6.3%
EPS (Basic)	-$0.32+40.7%	-$0.50+9.1%	-$0.33+40.0%	-$0.49+16.9%	-$0.54+11.5%	-$0.55+15.4%	-$0.55+16.7%	-$0.59+9.2%
EPS (Diluted)	-$0.32+40.7%	-$0.50+9.1%	-$0.33+40.0%	-$0.49+16.9%	-$0.54+11.5%	-$0.55+15.4%	-$0.55+16.7%	-$0.59+9.2%
Diluted Shares (Avg)	9M+5.8%	9M+4.7%	N/A	9M+5.0%	9M+3.6%	9M+3.7%	N/A	8M+2.2%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

LSTA Balance Sheet

LSTA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$17.7M-49.3%	$35.0M-36.0%	$54.7M-25.1%	$73.0M-24.7%	$97.0M+169.5%	$36.0M+32.6%	$27.2M-39.1%	$44.6M-29.7%	$63.4M+18.4%	$53.5M-6.5%	$57.2M-54.7%	$126.3M+40.6%	$89.8M+65.1%	$54.4M-65.0%	$155.3M
Current Assets	$17.7M-48.8%	$34.6M-35.9%	$53.9M-25.0%	$71.9M-25.3%	$96.2M+172.2%	$35.3M+36.0%	$26.0M-41.1%	$44.1M-28.2%	$61.4M+149.1%	$24.6M-15.8%	$29.3M-19.3%	$36.3M-28.6%	$50.8M+204.2%	$16.7M-56.7%	$38.6M
Cash & Equivalents	$16.0M-1.6%	$16.2M-28.3%	$22.6M-29.7%	$32.2M+30.5%	$24.6M+49.3%	$16.5M+17.7%	$14.0M+36.2%	$10.3M-64.7%	$29.2M+312.1%	$7.1M-62.1%	$18.7M-2.7%	$19.2M-58.4%	$46.1M+235.8%	$13.7M+249.1%	$3.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$25.9M	$0	$0-100.0%	$7.1M	$0	$0-100.0%	$559
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M+14.1%	$1.1M+71.8%	$648K
Accounts Receivable	$0-100.0%	$900K	$0	N/A	N/A	N/A	N/A	N/A	$234K+69.0%	$139K-94.6%	$2.6M-17.5%	$3.1M+67.2%	$1.9M+76.6%	$1.1M+4.3%	$1.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$7.0M0.0%	$7.0M-72.2%	$25.2M+126.7%	$11.1M0.0%	$11.1M0.0%	$11.1M
Total Liabilities	$3.1M-44.7%	$5.7M-16.4%	$6.8M+1.3%	$6.7M+34.0%	$5.0M+33.2%	$3.8M-43.0%	$6.6M-7.4%	$7.1M-46.0%	$13.2M-72.9%	$48.6M+43.4%	$33.9M-50.3%	$68.2M+145.4%	$27.8M+30.9%	$21.2M-77.2%	$93.3M
Current Liabilities	$3.1M-45.3%	$5.6M-14.8%	$6.6M+3.2%	$6.4M+41.1%	$4.5M+29.0%	$3.5M-41.3%	$6.0M+6.4%	$5.6M-39.7%	$9.3M-56.0%	$21.2M+0.8%	$21.0M+29.4%	$16.2M+65.6%	$9.8M-1.4%	$9.9M-72.7%	$36.4M
Non-Current Liabilities	$72K0.0%	$72K-65.7%	$210K-35.8%	$327K-32.6%	$485K+90.9%	$254K-59.3%	$624K-58.6%	$1.5M-61.1%	$3.9M-86.3%	$28.4M-16.4%	$33.9M-50.3%	$68.2M+145.4%	$27.8M+28.7%	$21.6M-36.4%	$33.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$2.5M-76.7%	$10.8M-22.0%	$13.9M	$0	$0	N/A
Total Equity	$14.9M-49.8%	$29.6M-38.6%	$48.1M-27.7%	$66.6M-27.8%	$92.3M+183.9%	$32.5M+56.1%	$20.8M-44.8%	$37.7M-25.3%	$50.5M+934.2%	$4.9M-79.4%	$23.7M-59.5%	$58.5M-6.4%	$62.5M+88.5%	$33.2M-46.5%	$62.0M
Retained Earnings	-$564.7M-3.0%	-$548.1M-3.8%	-$528.1M-4.1%	-$507.2M-12.0%	-$453.0M-6.5%	-$425.6M-2.0%	-$417.4M-4.9%	-$398.0M-4.2%	-$381.8M+5.7%	-$404.8M-8.8%	-$372.1M-27.8%	-$291.2M-23.2%	-$236.4M-19.7%	-$197.4M-37.9%	-$143.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.0M-56.2%	$14.1M-51.5%	$17.7M-49.3%	$21.8M-43.0%	$25.2M-40.9%	$29.0M-39.9%	$35.0M-36.0%	$38.2M-34.2%
Current Assets	$11.0M-55.7%	$14.0M-51.0%	$17.7M-48.8%	$21.6M-42.8%	$24.9M-40.7%	$28.6M-39.8%	$34.6M-35.9%	$37.7M-34.1%
Cash & Equivalents	$10.4M-38.0%	$13.1M-35.4%	$16.0M-1.6%	$19.0M-2.6%	$16.8M-40.5%	$20.2M-7.3%	$16.2M-28.3%	$19.5M-39.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	$0-100.0%	$502K	$501K	$750K	$900K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.0M-30.7%	$3.4M-12.7%	$3.1M-44.7%	$4.6M-2.6%	$4.4M-4.2%	$3.9M-29.4%	$5.7M-16.4%	$4.8M-11.6%
Current Liabilities	$3.0M-30.7%	$3.3M-12.9%	$3.1M-45.3%	$4.6M-2.6%	$4.3M-3.2%	$3.8M-28.6%	$5.6M-14.8%	$4.7M-8.6%
Non-Current Liabilities	$50K-30.6%	$72K0.0%	$72K0.0%	$72K0.0%	$72K-39.5%	$72K-56.1%	$72K-65.7%	$72K-71.5%
Total Equity	$8.2M-60.8%	$10.9M-56.9%	$14.9M-49.8%	$17.4M-48.4%	$21.0M-45.0%	$25.4M-41.0%	$29.6M-38.6%	$33.7M-36.4%
Retained Earnings	-$572.1M-2.6%	-$569.1M-3.0%	-$564.7M-3.0%	-$561.7M-3.4%	-$557.4M-3.5%	-$552.8M-3.6%	-$548.1M-3.8%	-$543.5M-4.0%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

LSTA Cash Flow Statement

LSTA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$12.3M	-$15.9M+17.6%	-$19.4M+3.4%	-$20.0M+5.4%	-$21.2M+4.8%	-$22.2M-152.1%	-$8.8M+53.3%	-$18.9M+5.5%	-$20.0M+4.3%	-$20.9M+11.8%	-$23.7M+39.7%	-$39.3M+16.3%	-$46.9M-73.0%	-$27.1M-95.6%	-$13.9M+33.8%	-$20.9M
Depreciation & Amortization	N/A	$146K-16.1%	$174K-7.9%	$189K+173.9%	$69K+25.5%	$55K-45.0%	$100K0.0%	$100K-50.0%	$200K-50.0%	$400K-20.0%	$500K-76.2%	$2.1M+31.3%	$1.6M+60.0%	$1.0M0.0%	$1.0M-30.6%	$1.4M
Stock-Based Compensation	N/A	$1.2M-25.8%	$1.7M-18.9%	$2.0M-22.7%	$2.6M+31.5%	$2.0M+58.5%	$1.3M-2.3%	$1.3M-47.2%	$2.5M-14.0%	$2.9M+9.5%	$2.6M-73.3%	$9.8M-13.0%	$11.2M+63.9%	$6.8M+1.9%	$6.7M-34.6%	$10.3M
Capital Expenditures	$0	$28K	$0	$0-100.0%	$285K+375.0%	$60K+200.0%	$20K	$0-100.0%	$134K-0.7%	$135K-87.7%	$1.1M-65.5%	$3.2M-12.9%	$3.7M+35.9%	$2.7M+406.6%	$531K-7.6%	$575K
Free Cash Flow	-$12.3M	-$16.0M+17.5%	-$19.4M+3.4%	-$20.0M+6.6%	-$21.5M+3.8%	-$22.3M-152.2%	-$8.8M+53.2%	-$18.9M+6.2%	-$20.1M+4.2%	-$21.0M+15.2%	-$24.8M+41.6%	-$42.4M+16.0%	-$50.6M-69.7%	-$29.8M-107.1%	-$14.4M+33.1%	-$21.5M
Investing Cash Flow	$5.2M	$15.1M+14.0%	$13.2M+31.0%	$10.1M-65.1%	$28.9M+152.7%	-$54.9M-654.4%	-$7.3M-134.0%	$21.4M+555.3%	-$4.7M-111.4%	$41.3M+1548.5%	-$2.8M-175.0%	$3.8M+135.4%	-$10.7M-298.9%	-$2.7M-144.2%	$6.1M+396.3%	-$2.1M
Financing Cash Flow	$768K	$599K+390.8%	-$206K-153.5%	$385K+271.9%	-$224K-100.3%	$85.3M+359.0%	$18.6M+1470.6%	$1.2M+43.6%	$824K+188.4%	-$932K-104.5%	$20.9M-42.9%	$36.6M+19.3%	$30.7M-50.7%	$62.2M+611.4%	$8.7M-56.4%	$20.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$328K	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.6M+33.0%	-$3.1M+42.9%	-$3.2M+28.2%	-$3.3M-32.7%	-$4.0M+25.1%	-$5.4M+23.1%	-$4.5M-11.3%	-$2.5M+29.7%
Depreciation & Amortization	$3K-93.2%	$2K-95.3%	$15K-63.4%	$44K+4.8%	$44K-2.2%	$43K-6.5%	$41K	$42K-10.6%
Stock-Based Compensation	$214K-10.5%	$364K-31.3%	N/A	$232K-29.1%	$239K+0.8%	$530K+16.7%	N/A	$327K+6.9%
Capital Expenditures	$0	$0-100.0%	$0	$0	$0	$28K	$0	$0
Free Cash Flow	-$2.6M+33.0%	-$3.1M+43.2%	-$3.2M+28.2%	-$3.3M-32.7%	-$4.0M+25.1%	-$5.4M+22.7%	-$4.5M-11.3%	-$2.5M+29.7%
Investing Cash Flow	$0-100.0%	$0-100.0%	$0-100.0%	$5.2M+181.7%	$505K-95.7%	$9.4M+46.5%	$1.4M+124.3%	-$6.3M-151.5%
Financing Cash Flow	$29K-54.7%	$181K+887.0%	$205K+313.5%	$353K	$64K+100.0%	-$23K+83.8%	-$96K-500.0%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LSTA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11.8%+1.4pp	10.4%-2.2pp	12.6%+0.9pp	11.7%-4.9pp	16.6%+2.6pp	14.0%
Operating Margin	-10711.2%	-2240.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-83.6%	-506.3%	-321.9%	-250.9%	-212.0%	-338.4%
Net Margin	-9756.5%	-1998.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-92.5%	-360.3%	-305.9%	-265.8%	-375.2%	-469.0%
Return on Equity	-111.7%-44.1pp	-67.6%-24.3pp	-43.3%+38.2pp	-81.5%-51.7pp	-29.8%-4.7pp	-25.1%+67.9pp	-93.0%-50.2pp	-42.9%-88.3pp	45.5%+714.1pp	-668.6%-327.0pp	-341.6%-247.8pp	-93.8%-31.4pp	-62.3%+99.7pp	-162.1%-86.1pp	-76.0%
Return on Assets	-93.5%-36.4pp	-57.1%-19.0pp	-38.1%+36.2pp	-74.3%-45.9pp	-28.3%-5.7pp	-22.6%+48.7pp	-71.3%-35.0pp	-36.3%-72.5pp	36.3%+97.3pp	-61.0%+80.6pp	-141.6%-98.2pp	-43.5%-0.1pp	-43.4%+55.4pp	-98.8%-68.5pp	-30.3%
Current Ratio	5.76-0.4x	6.16-2.0x	8.18-3.1x	11.26-10.0x	21.27+11.2x	10.08+5.7x	4.35-3.5x	7.85+1.3x	6.59+5.4x	1.16-0.2x	1.39-0.8x	2.23-2.9x	5.18+3.5x	1.68+0.6x	1.06
Debt-to-Equity	0.210.0x	0.19+0.1x	0.140.0x	0.100.0x	0.05-0.1x	0.12-0.2x	0.32+0.1x	0.19+0.2x	0.00-0.5x	0.52+0.1x	0.46+0.2x	0.24+0.2x	0.000.0x	0.00-1.5x	1.50
Asset Turnover	0.010.0x	0.030.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A	0.66+0.3x	0.39+0.3x	0.140.0x	0.16-0.1x	0.26+0.2x	0.06
FCF Margin	-9398.2%	-1935.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-70.2%	-188.7%	-281.8%	-203.1%	-100.4%	-214.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	-6954.3%	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-6655.7%	N/A	N/A	N/A
Return on Equity	-35.5%-13.4pp	-41.1%-22.5pp	N/A	-24.5%-9.8pp	-22.2%-9.0pp	-18.6%-6.1pp	N/A	-14.6%-4.7pp
Return on Assets	-26.6%-8.0pp	-31.9%-15.6pp	N/A	-19.5%-6.6pp	-18.5%-6.7pp	-16.3%-5.1pp	N/A	-12.9%-3.8pp
Current Ratio	3.69-2.1x	4.23-3.3x	5.76-0.4x	4.72-3.3x	5.77-3.6x	7.52-1.4x	6.16-2.0x	8.04-3.1x
Debt-to-Equity	0.37+0.2x	0.31+0.2x	0.210.0x	0.27+0.1x	0.21+0.1x	0.150.0x	0.19+0.1x	0.140.0x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x
FCF Margin	N/A	N/A	N/A	N/A	-5651.4%	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Lisata Therapeutics, Inc. LSTA	FY2025	$170K	-$16.6M	N/A	$13.6M	—
Hoth Therapeutics, Inc. HOTH	FY2025	N/A	-$12.5M	N/A	$26.0M	—
Curis Inc CRIS	FY2025	$9.4M	-$7.6M	-80.3%	$1.9M	42/100
ProMIS Neurosciences Inc. PMN	FY2025	N/A	-$39.7M	N/A	$84.3M	—
Citius Pharmaceuticals Inc. CTXR	FY2025	N/A	-$39.7M	N/A	$14.6M	—

Where Lisata Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Lisata Therapeutics, Inc.'s annual revenue?

Lisata Therapeutics, Inc. (LSTA) reported $170K in total revenue for fiscal year 2025. This represents a -83.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lisata Therapeutics, Inc.'s revenue growing?

Lisata Therapeutics, Inc. (LSTA) revenue declined by 83.0% year-over-year, from $1.0M to $170K in fiscal year 2025.

Is Lisata Therapeutics, Inc. profitable?

No, Lisata Therapeutics, Inc. (LSTA) reported a net income of -$16.6M in fiscal year 2025.

What is Lisata Therapeutics, Inc.'s EBITDA?

Lisata Therapeutics, Inc. (LSTA) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lisata Therapeutics, Inc.'s return on equity (ROE)?

Lisata Therapeutics, Inc. (LSTA) has a return on equity of -111.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lisata Therapeutics, Inc.'s free cash flow?

Lisata Therapeutics, Inc. (LSTA) recorded an outflow of $16.0M in free cash flow during fiscal year 2025. This represents a 17.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lisata Therapeutics, Inc.'s operating cash flow?

Lisata Therapeutics, Inc. (LSTA) recorded an outflow of $15.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lisata Therapeutics, Inc.'s total assets?

Lisata Therapeutics, Inc. (LSTA) had $17.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lisata Therapeutics, Inc.'s capital expenditures?

Lisata Therapeutics, Inc. (LSTA) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lisata Therapeutics, Inc. spend on research and development?

Lisata Therapeutics, Inc. (LSTA) invested $7.9M in research and development during fiscal year 2025.

How many shares does Lisata Therapeutics, Inc. have outstanding?

Lisata Therapeutics, Inc. (LSTA) had 9M shares outstanding as of fiscal year 2025.

What is Lisata Therapeutics, Inc.'s current ratio?

Lisata Therapeutics, Inc. (LSTA) had a current ratio of 5.76 as of fiscal year 2025, which is generally considered healthy.

What is Lisata Therapeutics, Inc.'s debt-to-equity ratio?

Lisata Therapeutics, Inc. (LSTA) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lisata Therapeutics, Inc.'s return on assets (ROA)?

Lisata Therapeutics, Inc. (LSTA) had a return on assets of -93.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lisata Therapeutics, Inc.'s P/E ratio?

Lisata Therapeutics, Inc. (LSTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $13.6M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Lisata Therapeutics, Inc.'s price-to-sales ratio?

Lisata Therapeutics, Inc. (LSTA) trades at 80.1x sales, its market capitalization divided by revenue of $170K revenue, FY2025. The market capitalization is $13.6M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Lisata Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Lisata Therapeutics, Inc. (LSTA) held $16.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.9M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Lisata Therapeutics, Inc.'s Altman Z-Score?

Lisata Therapeutics, Inc. (LSTA) has an Altman Z-Score of -44.34, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lisata Therapeutics, Inc.'s Piotroski F-Score?

Lisata Therapeutics, Inc. (LSTA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lisata Therapeutics, Inc.'s earnings high quality?

Lisata Therapeutics, Inc. (LSTA) reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.